Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.70 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.59 |
| ▸ | DRD3 | P35462 | 4/20 | 0.54 |
| ▸ | DRD1 | P21728 | 2/20 | 0.54 |
| ▸ | DRD4 | P21917 | 2/20 | 0.54 |
| ▸ | DRD5 | P21918 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.53 |
| ▸ | HRH2 | P25021 | 1/20 | 0.52 |
| ▸ | PDE2A | O00408 | 1/20 | 0.52 |
| ▸ | CNR2 | P34972 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10352098 | 0.99 | DRD2 (0.68) | DRD2SIGMAR1DRD3DRD1DRD4 | |
| SCHEMBL22928142 | 0.92 | DRD2 (0.62) | DRD2SIGMAR1MEN1KMT2ACHRM4 | |
| SCHEMBL6353029 | 0.92 | DRD2 (0.62) | DRD2SIGMAR1MEN1KMT2ACHRM4 | |
| SCHEMBL10656309 | 0.86 | DRD2 (0.71) | DRD2SIGMAR1DRD3DRD1DRD4 | |
| SCHEMBL10653140 | 0.86 | DRD2 (0.71) | DRD2SIGMAR1DRD3DRD1DRD4 | |
| SCHEMBL10653134 | 0.86 | DRD2 (0.71) | DRD2SIGMAR1DRD3DRD1DRD4 | |
| SCHEMBL8437990 | 0.84 | DRD2 (0.81) | DRD2SIGMAR1DRD3DRD1DRD4 | |
| SCHEMBL7353465 | 0.84 | DRD2 (0.81) | DRD2SIGMAR1DRD3DRD1DRD4 | |
| SCHEMBL11623316 | 0.82 | PDE4A (0.59) | SIGMAR1MEN1KMT2A | |
| SCHEMBL28226193 | 0.82 | CYP1A2 (0.66) | DRD2DRD3DRD1DRD4DRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9139525-B2 | N-oxide and/or di-N-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2015-09-22 | — | — | US | disclosed |
| US-20100105736-A1 | N-OXIDE AND/OR DI-N-OXIDE DERIVATIVES OF DOPAMINE RECEPTOR STABILIZERS/MODULATORS DISPLAYING IMPROVED CARDIOVASCULAR SIDE-EFFECTS PROFILES | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2010-04-29 | — | — | US | disclosed |
| EP-2146961-A1 | N-OXIDE AND/OR DI-N-OXIDE DERIVATIVES OF DOPAMINE RECEPTOR STABILIZERS/MODULATORS DISPLAYING IMPROVED CARDIOVASCULAR SIDE-EFFECTS PROFILES | NSAB, Filial af NeuroSearch Sweden AB, Sverige (DK) | 2010-01-27 | — | — | EP | disclosed |
| WO-2008127188-A1 | N-OXIDE AND/OR DI-N-OXIDE DERIVATIVES OF DOPAMINE RECEPTOR STABILIZERS/MODULATORS DISPLAYING IMPROVED CARDIOVASCULAR SIDE-EFFECTS PROFILES | ALLBAY AB (SE) | 2008-10-23 | — | — | WO | disclosed |
| EP-0097628-B1 | PIPERIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL PREPARATION CONTAINING THEM | Carlsson, Per Arvid Emil (SE) | 1990-09-19 | — | — | EP | disclosed |
| US-4937346-A | Phenyl-azacykloalkanes | Carlsson, Per Arvid Emil (SE) | 1990-06-26 | — | — | US | disclosed |
| EP-0105243-B1 | SEPARATION OF RACEMIC 1-PROPYL-3-ARYL PIPERIDINES | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1988-08-03 | — | — | EP | disclosed |
| US-4719219-A | Phenyl-azacycloalkanes and use thereof in treatment of central nervous system disorders | Carlsson, Per A. E. (SE) | 1988-01-12 | — | — | US | disclosed |
| EP-0105243-A2 | Separation of racemic 1-propyl-3-aryl piperidines | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1984-04-11 | — | — | EP | disclosed |
| EP-0105243-A2 | Separation of racemic 1-propyl-3-aryl piperidines | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1984-04-11 | — | — | EP | disclosed |
| EP-0097628-A2 | Piperidine derivatives, processes for their preparation and pharmaceutical preparation containing them | Carlsson, Per Arvid Emil (SE) | 1984-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105736-A1 | N-OXIDE AND/OR DI-N-OXIDE DERIVATIVES OF DOPAMINE RECEPTOR STABILIZERS/MODULATORS DISPLAYING IMPROVED CARDIOVASCULAR SIDE-EFFECTS PROFILES | CHRM4, GPR4, HTR4 | DRD2 66/4885SIGMAR1 27/4885DRD3 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.